Longeveron, a clinical stage biotech, has tapped Jerome Bailey as VP of business operations.
Bailey has more than three decades of leadership experience, most recently serving as senior director of program management at Checkmate Pharmaceuticals, which was acquired by Regeneron for $250 million. He also held management roles at Parexel, Covance and Eli Lilly.
“Jerome’s broad experience in portfolio management and clinical operations across multiple therapeutic areas makes him an invaluable addition to our team as we advance our lead medicinal signaling cell therapy product, Lomecel-B, through clinical trials in three indications,” Longeveron interim CEO Dr. Chris Min said in a statement.
